Selank is a synthetic peptide that was developed in Russia in the 1990s. It is a derivative of the naturally occurring peptide tuftsin, which is found in the human immune system. Selank has been studied for its potential therapeutic effects, including anti-anxiety, anti-depressant, and cognitive enhancing effects.
The history of Selank begins with the development of tuftsin, which was first discovered in the 1970s. Tuftsin is a tetrapeptide (four amino acids) that is produced by the immune system to help regulate the immune response. In the 1980s, Russian scientists began studying tuftsin and its potential therapeutic effects.
One of the key researchers involved in the development of Selank was Nikolay Myasoedov, a Russian biochemist who worked at the Institute of Molecular Genetics in Moscow. Myasoedov and his colleagues were interested in developing a synthetic peptide that could mimic the effects of tuftsin, but with greater stability and bioavailability.
In the early 1990s, Myasoedov and his team developed Selank, a modified version of tuftsin that contains an additional four amino acids. Selank was designed to be more stable and more easily absorbed by the body than tuftsin.
Initial studies on Selank focused on its effects on the immune system. A study published in the journal Immunology in 1997 found that Selank had immunomodulatory effects in rats, increasing the activity of natural killer cells and improving the immune response to a bacterial infection.
However, it was not long before researchers began to explore the potential therapeutic effects of Selank on the brain. A study published in the journal Neuropharmacology in 2002 found that Selank had anxiolytic effects in rats, reducing anxiety-like behavior in a maze test. The researchers also found that Selank increased the activity of the neurotransmitter GABA, which is involved in the regulation of anxiety.
Since then, a number of studies have been conducted on the potential therapeutic effects of Selank on the brain. In addition to its anxiolytic effects, Selank has been studied for its potential anti-depressant effects. A study published in the journal Behavioural Brain Research in 2014 found that Selank had anti-depressant effects in rats, reducing the duration of immobility in a forced swim test.
Selank has also been studied for its potential cognitive enhancing effects. A study published in the journal Neurochemical Research in 2016 found that Selank improved memory and learning in rats, possibly by increasing levels of the protein BDNF in the brain.
Despite these promising results, there is still much that is not known about Selank and its potential therapeutic effects. It is not clear, for example, how Selank exerts its anxiolytic and anti-depressant effects, or how it affects the immune system. In addition, many of the studies on Selank have been conducted in animal models, and more research is needed to determine whether these findings translate to humans.
It is also worth noting that Selank is not approved for medical use in many countries, including the United States. While the compound is available for research purposes, it is not approved for human consumption or for the treatment of any medical conditions.
In conclusion, Selank is a synthetic peptide that was developed in Russia in the 1990s. It is a derivative of the naturally occurring peptide tuftsin and has been studied for its potential therapeutic effects, including anti-anxiety, anti-depressant, and cognitive enhancing effects. While the compound has shown promise in animal models, more research is needed to determine its potential therapeutic effects and its safety and efficacy in humans.